Blog
Supporting the creation of new biotech companies from academia
With the launch of Axovia Therapeutics, a biotech company in the gene therapy space, Dr. Nick Meyers, VP and Head of Product Development & Programme Management at Boyds reflects on the team’s involvement in the company’s formation. With recent advances in bioengineering and genetics, the therapeutic options for treating genetic diseases, especially monogenic diseases have broadened and are it seems, expanding exponentially. The delivery of gene therapy requires the use of viral vector (e.g., adenoviruses, adeno-associated viruses, lentiviruses) or nanoparticle
Programme management: the backbone of successful product development
An increasing number of academic groups, new start-ups, biotechs and small pharma companies are turning to Boyds for professional programme management support and guidance to help them progress their ideas into medicines for patients. Dr. Nick Meyers, Vice President of Product Development at Boyds, reflects on the benefits of putting a credible development plan in place from an early stage to help navigate the pathway, overcome challenges and improve efficiencies. One indirect effect of the COVID pandemic, and the successful
Supporting the development of treatments for rare diseases – it’s in our DNA
To mark Rare Disease Day 2021, Professor Alan Boyd reflects on the work that he and his colleagues carry out to support the development of advanced cell and gene therapies to treat orphan diseases. Rare Disease Day aims to raise awareness of the 300 million people across the globe that are living with a rare disease. In Europe, a disease is considered to be rare when it affects fewer than 1 in 2000 people, and there are approximately 6,000 rare
Preventing fake medicines from reaching patients
Boyds’ Director of Regulatory Affairs, Julie Warner, has co-edited an article in the October issue of the TOPRA journal, Regulatory Rapporteur, which focuses on falsified medicines. The following article was published in Regulatory Rapporteur, Volume 16, No 10, October 2019. Preventing fake medicines from reaching patients By Julie Warner, Director Regulatory Affairs, Alan Boyd Consultants, UK Andrew Germain, Associate Director Regulatory Affairs CMC, GW Pharmaceuticals, UK Safety feature requirements for prescription and some over-the-counter medicines have now been
Overcoming the Barriers to the Development of Medicines for Ultra Rare Diseases
In the third and final article in the series on Orphan Drugs, Bryan Hurst discusses how to overcome the barriers to the development of medicines for the treatment of ultra-rare diseases. To read the first article on orphan drugs, click here, and for the second article, click here. The decision to invest in developing a treatment for a rare disease inevitably hinges on the potential for profit or loss unless funded by a charity or government. In the case of
Orphan Drug Development
This is the first in a series of articles aiming to highlight the vital role that drug development consultants play in helping small pharma companies to bring new medicines to the market. To put this properly into context it is essential to understand the way drug development has changed. The big pharmaceutical companies that totally dominated drug development in previous decades have had to face a new set of challenges in the new millennium. The highly profitable blockbuster drugs needed
